#57 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
# Why This Matters for Clinicians and Patients
Clinicians need evidence-specific guidance on cannabis use in older adults to counsel patients safely, as this population has unique pharmacokinetics, drug interactions, and fall risk that differ from younger users. Understanding why seniors prefer edibles (likely slower onset, longer duration, and perceived safety) helps clinicians assess dosing risks and educate patients about delayed effects that may lead to overconsumption. This research fills a critical gap in geriatric cannabis medicine and enables more informed shared decision-making about risks and benefits in an aging population increasingly turning to these products.
A University study examining cannabis use patterns in adults over 60 found that older adults increasingly prefer edibles over other delivery methods, reflecting both safety considerations and practical appeal in this demographic. The research highlights a significant gap in evidence-based knowledge about cannabis pharmacology, efficacy, and safety specific to older populations, who often have altered metabolism, polypharmacy concerns, and increased vulnerability to adverse effects. Understanding why seniors gravitate toward edibles is clinically important, as edibles present distinct pharmacokinetic profiles including delayed onset and prolonged duration that may pose risks for falls, cognitive impairment, or drug interactions in geriatric patients. The study underscores the need for better clinical guidance and rigorous research in cannabis use among older adults, particularly given the aging population’s growing interest in cannabis for chronic pain, sleep, and other conditions. Clinicians caring for older patients should proactively discuss cannabis use, assess for edible consumption patterns, counsel on dosing risks specific to this population, and advocate for more robust safety data to inform prescribing and harm reduction strategies.
💊 The emerging preference for cannabis edibles among older adults reflects both a legitimate clinical opportunity and a significant knowledge gap that warrants cautious consideration. Older patients may be drawn to edibles for valid reasons including easier administration compared to smoking, perceived discretion, and potential for sustained symptom relief, yet this population has unique pharmacokinetic vulnerabilities including altered metabolism, polypharmacy risks, and increased fall and cognitive side effects that are poorly characterized in the current literature. Clinicians should recognize that the lack of rigorous evidence in geriatric populations does not mean cannabis is unsafe or ineffective for this age group, but rather that individualized risk-benefit discussions must account for limited data on drug interactions, delayed onset effects that may lead to accidental overdosing, and particular susceptibility to adverse events. When older patients inquire about or use cannabis edibles, providers should ask about specific indications, concurrent medications, baseline cognition and fall risk,
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
